Fas, fas ligand, and transfusion immunomodulation

Transfusion

Volumn 41, Issue 3, 2001, Pages 416-418

  Puppo, Francesco ^a,b,c   Ghio, Massimo ^a,b   Contini, Paola ^a,b   Mazzei, Clemente ^a,b   Indiveri, Francesco ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b Imperia Hospital   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND; FRESH FROZEN PLASMA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; APOPTOSIS; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; ERYTHROCYTE PRESERVATION; HLA SYSTEM; HUMAN; IMMUNOMODULATION; MOUSE; NONHUMAN; PROTEIN FAMILY; SHORT SURVEY; T LYMPHOCYTE; THROMBOCYTE PRESERVATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD95; BLOOD TRANSFUSION; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS;

EID: 0035078205     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41030416.x     Document Type: Short Survey

References (19)

1. Fas and Fas ligand: A death factor and its receptor
2. Expression of the Fas ligand in cells of T cell lineage
3. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvescicles
4. Fas ligand in human serum
5. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils
6. Role of Fas-mediated cell death in the regulation of immune responses
7. Fas and Fas ligand: lpr and gld mutations
8. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas(CD95)(+) T lymphocytes
9. Cutting edge: Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8
10. Serum HLA class I antigens: Markers and modulators of an immune response?
11. Quantitation of soluble HLA class 1 antigen in human albumin and immunoglobulin preparations for intravenous use by solid-phase immunoassay
12. Soluble HLA class I and class II Concentrations in commercial immunoglobulin preparations
13. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations
14. Soluble HLA class I and class II concentrations in factor VIII and PCC preparations
15. Soluble HLA class I, HLA class II, and Fas ligand in blood components: A possible key to explain the immunomodulatory effects of allogeneic blood transfusions
16. Mechanisms of transfusion-associated immunosuppression
17. Blood transfusion and postoperative septic complications
18. Current research on the immunomodulatory effect of allogeneic blood transfusion
19. Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: Do we have the answers yet?